Clinical consequences of MRI activity in treated multiple sclerosis

Area of Science:

• Neurology
• Neuroimmunology
• Radiology

Background:

• Brain MRI inflammation is a key marker for multiple sclerosis (MS) disease activity.
• The clinical impact of MRI activity in MS patients remains debated.
• This study examines the clinical consequences of MRI activity in MS patients on first-line disease-modifying therapies.

Purpose of the Study:

• To investigate the clinical consequences of MRI activity in MS patients treated with interferon beta-1b or glatiramer acetate.
• To assess the relationship between MRI remission and clinical outcomes, including relapses, physical disability, and cognitive function.

Main Methods:

• The BECOME study included 75 treatment-naïve MS or at-risk clinically isolated syndrome patients.
• Participants were randomized to interferon beta-1b (n=39) or glatiramer acetate (n=36).
• Monthly brain MRIs were conducted for up to two years to monitor inflammatory activity and remission.

Main Results:

• Complete MRI remission was achieved by 23.2% of participants; 46.4% had transient remission, and 30.4% never achieved remission.
• No significant differences in MRI remission rates were observed between interferon beta-1b and glatiramer acetate.
• Lack of MRI remission was associated with higher relapse rates (p=0.017), worsening ambulatory function (p=0.026), and poorer cognitive function improvement (p<0.001).

Conclusions:

• Failure to achieve MRI remission during treatment with interferon beta-1b or glatiramer acetate is linked to adverse clinical outcomes in MS.
• These findings highlight the importance of monitoring MRI activity to predict and potentially mitigate disease progression.
• Optimizing treatment strategies to achieve MRI remission may be critical for managing physical and cognitive decline in MS.